DS-1055
/ Daiichi Sankyo
- LARVOL DELTA
Home
Next
Prev
1 to 14
Of
14
Go to page
1
August 05, 2025
Bidirectional anti-tumor and immunological strategies by targeting GARP-TGF-β axis in adult T-cell leukemia/lymphoma.
(PubMed, Leukemia)
- "DS-1055a, an anti-GARP monoclonal antibody, selectively and effectively depleted malignant ATL cells via antibody-dependent cellular cytotoxicity, supporting the proof-of-concept in the preclinical study. Our findings highlight the key to understanding the cell origin of ATL and developing unprecedented therapeutic strategies for refractory diseases."
Journal • Adult T-Cell Leukemia-Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • TGFB1
April 09, 2025
A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors
(clinicaltrials.gov)
- P1 | N=40 | Active, not recruiting | Sponsor: Daiichi Sankyo Co., Ltd. | Recruiting ➔ Active, not recruiting | Trial completion date: Jun 2025 ➔ Jan 2026 | Trial primary completion date: Jun 2025 ➔ Jan 2026
Enrollment closed • Trial completion date • Trial primary completion date • Esophageal Cancer • Gastric Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor
November 12, 2024
A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors
(clinicaltrials.gov)
- P1 | N=40 | Recruiting | Sponsor: Daiichi Sankyo Co., Ltd. | Trial completion date: Dec 2024 ➔ Jun 2025 | Trial primary completion date: Dec 2024 ➔ Jun 2025
Trial completion date • Trial primary completion date • Esophageal Cancer • Gastric Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor
March 08, 2023
A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors
(clinicaltrials.gov)
- P1 | N=40 | Recruiting | Sponsor: Daiichi Sankyo Co., Ltd. | Trial primary completion date: Mar 2023 ➔ Dec 2024
Metastases • Trial primary completion date • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor
March 11, 2021
[VIRTUAL] Anti-GARP antibody DS-1055a augments antitumor immunity by depleting highly suppressive GARP+ regulatory T cells
(AACR 2021)
- P1 | "From these results, we propose that DS-1055a can be a new Treg cell-targeted regent that augments antitumor T cell immunity by depleting GARP+ Treg cells. Currently, a Phase I study of DS-1055a is on-going (NCT04419532)."
Oncology • CD4 • CD8 • FOXP3
February 10, 2023
A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors
(clinicaltrials.gov)
- P1 | N=40 | Recruiting | Sponsor: Daiichi Sankyo Co., Ltd. | Trial completion date: Mar 2023 ➔ Dec 2024
Metastases • Trial completion date • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor
August 01, 2022
"SVB cites one other anti-GARP in clinical development, $DSNKY's DS-1055a"
(@ByMadeleineA)
Clinical
July 09, 2021
Novel anti-GARP antibody DS-1055a augments antitumor immunity by depleting highly suppressive GARP + regulatory T cells.
(PubMed, Int Immunol)
- "Moreover, DS-1055a decreased FoxP3 +CD4 + T cells in the TME and exhibited remarkable antitumor activity in a humanized mouse bearing HT29 tumor. We propose that DS-1055a is a new Treg-cell-targeted cancer immunotherapy agent with augmentation of antitumor immunity."
Journal • Immune Modulation • Immunology • Inflammation • Oncology • CD4 • FOXP3
April 07, 2021
"uh-huh 1847 - Anti-GARP antibody DS-1055a augments antitumor immunity by depleting highly suppressive GARP+ regulatory T cells #AACR21"
(@PDRennert)
Oncology
December 22, 2020
Use of Autochthonous Lactiplantibacillus plantarum Strains to Produce Fermented Fish Products.
(PubMed, Front Microbiol)
- "plantarum 11, L. plantarum 69, and L. plantarum DSM1055) at 10 cfu/g and incubated at 10, 20, or 30°C for 7 days...In the second step, salami-like were produced according to the individuated formulation and inoculated with the studied starters (10 cfu/g); the fish mixture was stuffed into a natural casing and left to ferment at 30°C for 7 days. The use of the selected strains not only assured a correct fermentation but reduced the process time at only 2 days; during refrigerated storage, a good microbiological, chemico-physical and sensorial quality of the final product was recorded for at least 21 days."
Journal
October 22, 2020
BioInvent receives €2 million milestone from Daiichi Sankyo
(PRNewswire)
- "BioInvent...today announces that it will receive a €2 million milestone payment under its collaboration with Daiichi Sankyo related to the initiation of a global Phase I clinical trial with an anti-glycoprotein A repetitions predominant (GARP) directed antibody...in adult patients with advanced or metastatic solid tumors."
Financing • Oncology • Solid Tumor
October 22, 2020
Daiichi Sankyo Initiates Phase 1 Trial with Immuno-Oncology Therapy DS-1055 Targeting GARP on Activated Regulatory T Cells
(Businesswire)
- "Daiichi Sankyo...announced today that the first patient has been dosed in a first-in-human global phase 1 study evaluating DS-1055, a GARP directed immuno-oncology therapy, in patients with advanced or metastatic solid tumors who have progressed on standard treatments including checkpoint inhibitors."
Trial status • Oncology • Solid Tumor
October 19, 2020
A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors
(clinicaltrials.gov)
- P1; N=40; Recruiting; Sponsor: Daiichi Sankyo Co., Ltd.; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor
June 05, 2020
A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors
(clinicaltrials.gov)
- P1; N=40; Not yet recruiting; Sponsor: Daiichi Sankyo Co., Ltd.
Clinical • New P1 trial • Esophageal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor
1 to 14
Of
14
Go to page
1